Aptamer: A theranostic approach towards breast cancer

Rana, Shelly; Kaushik, Deepti; Singh, Aprajita; Gautam, D.; Rai, J.; Rathore, Jitendra Singh

doi:10.1016/j.clicom.2023.06.002

Cited by 3 publications

(2 citation statements)

References 178 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 The exploration of aptamers for breast cancer cell detection is an exciting and evolving field of research. While advancements have been made in targeting metastatic breast cancer cells, [7][8][9] there is a pressing need to expand this research to encompass primary tumor sites. Aptamers have the potential to redefine breast cancer diagnostics, offering improvements in sensitivity and specificity that could significantly impact patient outcomes.…”

Section: Resultsmentioning

confidence: 99%

“…7,8 Other classes of aptamers can also address therapeutic agents in the intracellular compartment, concentrating them around and inside specific cells or tissues and reducing their adverse effects. 9,10 While aptamers have shown promise in detecting breast cancer cells, it is noteworthy that a significant gap exists in the literature concerning the generation of aptamers specifically designed for cells derived from tumors from primary sites. 11 The limited exploration of aptamers for primary breast cancer cells leaves a critical void in our understanding of the potential of aptamers in the early stage of the disease for theranostic applications.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Selection of internalizing RNA aptamers into human breast cancer cells derived from primary sites

Cunha,

de Miranda,

de Melo

et al. 2024

J of Cellular Biochemistry

View full text Add to dashboard Cite

Breast cancer is the most common cancer in women. Although chemotherapy is still broadly used in its treatment, adverse effects remain a challenge. In this scenario, aptamers emerge as a promising alternative for theranostic applications. Studies using breast cancer cell lines provide useful information in laboratory and preclinical investigations, most of which use cell lines established from metastatic sites. However, these cell lines correspond to cell populations of the late stage of tumor progression. On the other hand, studies using breast cancer cells established from primary sites make it possible to search for new theranostic approaches in the early stages of the disease. Therefore, this work aimed to select RNA aptamers internalized by MGSO‐3 cells, a human breast cancer cell line, derived from a primary site previously established in our laboratory. Using the Cell‐Internalization SELEX method, we have selected two candidate aptamers (ApBC1 and ApBC2). We evaluated their internalization efficiencies, specificities, cellular localization by Reverse Transcription‐qPCR (RT‐qPCR) and confocal microscopy assays. The results suggest that both aptamers were efficiently internalized by human breast cancer cells, MACL‐1, MDA‐MB‐231, and especially by MGSO‐3 cells. Furthermore, both aptamers could effectively distinguish human breast cancer cells derived from normal human mammary cell (MCF 10A) and prostate cancer cell (PC3) lines. Therefore, ApBC1 and ApBC2 could be promising candidate molecules for theranostic applications, even in the early stages of tumor progression.

show abstract